KRAS and adenocarcinoma: The prevalence of other top-mutated genes, PIK3CA in SCC and KRAS in adenocarcinoma, from Inuit cases is comparable to global cases seen in cBioPortal [12] and raises the possibility that novel inhibitors of phosphatidylinositol 3-kinase (PI3K) and KRAS may have value in this population if ongoing clinical trials report positive results in the future.